{
  "Country": "PO",
  "PICOs": [
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have experienced disease progression after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel (DOC)",
      "Outcomes": "Progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), quality of life (QoL), overall survival (OS), adverse events (AEs), treatment-related adverse events leading to discontinuation."
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have experienced disease progression after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Nintedanib in combination with Docetaxel (NIN+DOC)",
      "Outcomes": "Progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), quality of life (QoL), overall survival (OS), adverse events (AEs), treatment-related adverse events leading to discontinuation."
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have experienced disease progression after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Pemetrexed (PMX)",
      "Outcomes": "Progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), quality of life (QoL), overall survival (OS), adverse events (AEs), treatment-related adverse events leading to discontinuation."
    }
  ],
  "SourceType": "hta_submission"
}